Next 10 |
home / stock / azncf / azncf news
2024-07-19 06:50:00 ET Summary Parnassus Growth Equity Fund (Investor Shares) returned 3.74% (net of fees) for the quarter, underperforming the Russell 1000 Growth Index’s 8.33%. The underperformance was primarily driven by our stock selection in the Information Technology ...
2024-07-18 13:50:41 ET Summary AstraZeneca PLC will announce its Q2 earnings next Thursday, 25th July. In Q1, the company showed 19% year-on-year revenue growth and 13% EPS growth. Guidance for 2024 is for double-digit growth at the top and bottom lines — it's possible ...
2024-07-18 13:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International equities...
2024-07-17 04:42:00 ET Summary As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors. ...
2024-07-11 13:20:00 ET Summary We have had arguably one of the more dismal six months to report to Partners. Giant spreads between us and an index or our index and other indices tend to mean revert, but as has been noted often, this has been one helluva decade as far as pace of cl...
2024-07-10 12:19:05 ET Summary argenx SE's stock is down significantly from its all-time highs due to some clinical failures for its primary asset, Vyvgart. However, recent approval for a label expansion into CIDP has turned sentiment more positive, with the shares spurting forwar...
2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...
2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...
2024-06-25 12:54:41 ET Summary AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with N...
2024-06-21 14:31:06 ET Summary Silence Therapeutics plc results from the phase 1 SANRECO study, using divesiran for the treatment of patients with polycythemia vera, expected end of June 2024. The 7 major polycythemia vera markets are expected to reach $68.5 billion by 2034. P...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...